Differentiation of Human Embryonic Stem Cells
7 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
2 Citations
31 Claims
-
1. (canceled)
-
2. (canceled)
-
3. (canceled)
-
4. (canceled)
-
5. (canceled)
-
6. (canceled)
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. (canceled)
-
14. (canceled)
-
15. (canceled)
-
16. (canceled)
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. (canceled)
-
24. (canceled)
-
25. (canceled)
-
26. (canceled)
-
27. A method for treating a patient having diabetes by transplanting pancreatic endocrine cells into the patient wherein the cells are obtained by culturing pancreatic endoderm cells in medium supplemented with glucose at a concentration from about 10 mM to about 20 mM and treating with a factor selected from the group consisting of:
- a gamma secretase inhibitor, Exendin-4, and a combination of Exendin-4 and hepatocyte growth factor.
-
28. A method for treating a patient having diabetes by transplanting pancreatic endocrine cells into the patient, wherein the cells are obtained by culturing human pluripotent stem cells, differentiating the human pluripotent stem cells into definitive endoderm cells by treating the human pluripotent stem cells with activin A, differentiating the definitive endoderm cells into pancreatic endoderm cells by treating the definitive endoderm cells with at least one fibroblast growth factor, or with retinoic acid and at least one fibroblast growth factor, and differentiating the pancreatic endoderm cells by culturing the cells in medium supplemented with glucose at a concentration from about 10 mM to about 20 mM and treating with a factor selected from the group consisting of:
- a gamma secretase inhibitor, Exendin-4, and a combination of Exendin-4 and hepatocyte growth factor.
- View Dependent Claims (30, 31)
-
29. (canceled)
Specification